Novartis announced a $1.4 billion agreement to acquire Tourmaline Bio, gaining rights to a promising cardiovascular therapy originally developed at Pfizer. This acquisition aims to bolster Novartis’ cardiovascular portfolio with a phase 2–ready asset that showed encouraging efficacy signals. The deal involves a $48 per share cash payment, reflecting Novartis’ strategy to revitalize its presence in the cardiovascular therapeutic area with innovative candidates. The purchase is part of a broader trend of big pharma investing heavily in cardiovascular innovation.